[go: up one dir, main page]

DE60104697D1 - Sulfonamid-derivate - Google Patents

Sulfonamid-derivate

Info

Publication number
DE60104697D1
DE60104697D1 DE60104697T DE60104697T DE60104697D1 DE 60104697 D1 DE60104697 D1 DE 60104697D1 DE 60104697 T DE60104697 T DE 60104697T DE 60104697 T DE60104697 T DE 60104697T DE 60104697 D1 DE60104697 D1 DE 60104697D1
Authority
DE
Germany
Prior art keywords
sulfonamide derivatives
psychiatric
useful
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60104697T
Other languages
English (en)
Other versions
DE60104697T2 (de
Inventor
Allen Knobelsdorf
Alan Shepherd
George Tromiczak
Hamideh Zarrinmayeh
Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60104697D1 publication Critical patent/DE60104697D1/de
Application granted granted Critical
Publication of DE60104697T2 publication Critical patent/DE60104697T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
DE60104697T 2000-06-13 2001-05-30 Sulfonamid-derivate Expired - Fee Related DE60104697T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21136500P 2000-06-13 2000-06-13
US211365P 2000-06-13
PCT/US2001/010840 WO2001096289A1 (en) 2000-06-13 2001-05-30 Sulfonamide derivatives

Publications (2)

Publication Number Publication Date
DE60104697D1 true DE60104697D1 (de) 2004-09-09
DE60104697T2 DE60104697T2 (de) 2005-08-04

Family

ID=22786629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60104697T Expired - Fee Related DE60104697T2 (de) 2000-06-13 2001-05-30 Sulfonamid-derivate

Country Status (9)

Country Link
US (1) US6703425B2 (de)
EP (1) EP1296945B1 (de)
JP (1) JP2004503527A (de)
AT (1) ATE272617T1 (de)
AU (1) AU2001274806A1 (de)
CA (1) CA2411811A1 (de)
DE (1) DE60104697T2 (de)
ES (1) ES2225558T3 (de)
WO (1) WO2001096289A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6639107B1 (en) 1999-12-08 2003-10-28 Eli Lilly And Company Cyclopentyl sulfonamide derivatives
ZA200603864B (en) * 2003-10-28 2007-09-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
EP1944289B1 (de) * 2004-08-09 2010-05-19 Glaxo Group Limited Verbindungen zur Verstärkung der Glutamatrezeptorwirkung und deren Verwendung in der Medizin
US8007849B2 (en) * 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
JP2010517926A (ja) * 2006-02-08 2010-05-27 グラクソ グループ リミテッド グルタミン酸受容体を増強する、統合失調症の治療に有用な4−フェニル−3−(2−プロピルスルホニルアミノ)テトラヒドロフラン誘導体
US20070293573A1 (en) * 2006-02-24 2007-12-20 Eric Gouaux Glu2 receptor modulators
US20090270508A1 (en) * 2007-02-23 2009-10-29 James Eric Gouaux GluR2 receptor modulators
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2544688B1 (de) 2010-03-02 2016-09-07 President and Fellows of Harvard College Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
EP3008167A4 (de) 2013-06-13 2017-06-07 VeroScience LLC Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
WO2018009256A1 (en) 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders
CN109678812B (zh) * 2018-12-30 2022-09-02 天津大学 一种5-乙烯基-2-硫代恶唑烷的制备方法
US20230227607A1 (en) * 2020-08-20 2023-07-20 Mitsubishi Gas Chemical Company, Inc. Polyamide resin
KR102564274B1 (ko) * 2020-08-20 2023-08-07 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 폴리아미드 수지
KR20230165753A (ko) 2021-04-08 2023-12-05 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 에폭시 수지 경화제, 에폭시 수지 조성물 및 도료
WO2022230656A1 (ja) 2021-04-26 2022-11-03 三菱瓦斯化学株式会社 化合物及びその製造方法
CN118251444A (zh) 2021-11-18 2024-06-25 三菱瓦斯化学株式会社 聚酰胺树脂的制造方法及树脂组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161601C2 (ru) * 1995-02-01 2001-01-10 Фармация Энд Апджон Компани 2-аминоинданы в качестве селективных лигандов допамина д3
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
JP3817045B2 (ja) * 1997-09-12 2006-08-30 四国化成工業株式会社 溶融塩型高分子電解質
JP2002504502A (ja) * 1998-02-24 2002-02-12 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体
US6500865B1 (en) 1998-07-31 2002-12-31 Eli Lilly And Company Sulfonamide derivatives
ATE311362T1 (de) 2000-05-19 2005-12-15 Lilly Co Eli Verfahren zur herstellung von biphenyl- verbindungen
IL152156A0 (en) 2000-05-19 2003-05-29 Lilly Co Eli Sulfonamide derivatives

Also Published As

Publication number Publication date
US20030229102A1 (en) 2003-12-11
ES2225558T3 (es) 2005-03-16
US6703425B2 (en) 2004-03-09
JP2004503527A (ja) 2004-02-05
AU2001274806A1 (en) 2001-12-24
ATE272617T1 (de) 2004-08-15
WO2001096289A1 (en) 2001-12-20
EP1296945B1 (de) 2004-08-04
CA2411811A1 (en) 2001-12-20
EP1296945A1 (de) 2003-04-02
DE60104697T2 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
DE60104697D1 (de) Sulfonamid-derivate
FI950309A0 (fi) Proliiniamidijohdannaisia
AP2002002637A0 (en) Novel piperazine
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
YU94103A (sh) Novi derivati sulfonske kiseline
ID24846A (id) Turunan-turunan bifenilamidina
DE60120427D1 (de) Radicicol und monocillin und ihre analogen und ihre anwendungen
AP2001002306A0 (en) Bridged piperazine derivatives.
EA200201232A1 (ru) Производные сульфонамида
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
EA200201234A1 (ru) Производные сульфонамида
ATE298742T1 (de) Zykloalkenylsulfonamidderivate
AP2002002595A0 (en) Heterocyclic amide derivatives.
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
DE60211866D1 (de) Thiophen substituierte amin derivate als glyt-1 inhibitoren
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee